PET/MRI scan for PR-positive breast cancer before surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new PET/MRI scan (using a special tracer called 18F-FFNP) to see how it images progesterone-receptor-positive breast cancer before surgery. You would get the scan and then have your planned surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are postmenopausal (either had both ovaries removed, are 60 or older, or haven't had a period for a year)
- Your breast cancer is progesterone-receptor-positive (PR+) and at least 1 cm in size
- You are planning to have surgery first, without chemotherapy, targeted therapy, or hormone therapy beforehand
- You are not pregnant, not nursing, and have no allergy to the study drugs or MRI contrast
- You can lie face-down for 45 minutes and do not need strong sedation for the scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This early study tests a special PET scan (a type of imaging) to look at newly diagnosed ER-positive breast cancer. The goal is to see how well the scan can detect and measure cancer, which may help guide care.
This trial tests a focused radiation treatment before surgery for early-stage breast cancer that is hormone receptor positive and HER2 negative. The goal is to give precise radiation only to the tumor, with the hope of reducing side effects and improving outcomes.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.